MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs

Silvia Maifrede, Esteban Martinez, Margaret Nieborowska-Skorska, Daniela Di Marcantonio, Michael Hulse, Bac Viet Le, Huaqing Zhao, Katarzyna Piwocka, Italo Tempera, Stephen M. Sykes, Tomasz Skorski

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

PARP1 is required for the maintenance of MLL-AF9 leukemias.PARP1 inhibitors enhance the therapeutic effect of cytotoxic drugs against MLL-AF9 leukemias.

Original languageEnglish
Pages (from-to)1467-1472
Number of pages6
JournalBlood advances
Volume1
Issue number19
DOIs
StatePublished - Aug 22 2017

Fingerprint

Dive into the research topics of 'MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs'. Together they form a unique fingerprint.

Cite this